Organovo Holdings Inc (ONVO) Stake Raised by Vanguard Group Inc

Vanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most …

Organovo logoVanguard Group Inc grew its position in Organovo Holdings Inc (NASDAQ:ONVO) by 1.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,771,558 shares of the medical research company’s stock after acquiring an additional 52,073 shares during the quarter. Vanguard Group Inc owned about 4.12% of Organovo worth $5,487,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in shares of Organovo in the third quarter valued at $138,000. Renaissance Technologies LLC raised its stake in shares of Organovo by 179.2% in the second quarter. Renaissance Technologies LLC now owns 1,244,600 shares of the medical research company’s stock valued at $1,742,000 after acquiring an additional 798,800 shares during the period. Vanguard Group Inc. raised its stake in shares of Organovo by 1.1% in the third quarter. Vanguard Group Inc. now owns 4,771,558 shares of the medical research company’s stock valued at $5,487,000 after acquiring an additional 52,073 shares during the period. BlackRock Inc. raised its stake in shares of Organovo by 14.8% in the second quarter. BlackRock Inc. now owns 6,966,411 shares of the medical research company’s stock valued at $9,753,000 after acquiring an additional 897,113 shares during the period. Finally, ARK Investment Management LLC raised its stake in shares of Organovo by 20.8% in the third quarter. ARK Investment Management LLC now owns 17,951,107 shares of the medical research company’s stock valued at $20,644,000 after acquiring an additional 3,090,669 shares during the period. 36.22% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ ONVO traded up $0.01 during mid-day trading on Tuesday, reaching $1.01. The company had a trading volume of 11,445 shares, compared to its average volume of 560,614. The stock has a market cap of $119.49 million, a PE ratio of -3.16 and a beta of 1.84. Organovo Holdings Inc has a 52 week low of $0.90 and a 52 week high of $2.09.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Thursday, February 7th. The medical research company reported ($0.06) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.01. The firm had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $0.87 million. Organovo had a negative net margin of 770.79% and a negative return on equity of 67.55%. Research analysts forecast that Organovo Holdings Inc will post -0.25 earnings per share for the current year.

Several equities research analysts have recently weighed in on ONVO shares. Zacks Investment Research downgraded shares of Organovo from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. HC Wainwright initiated coverage on shares of Organovo in a report on Thursday, December 13th. They issued a “buy” rating and a $2.50 price target on the stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Fairfield Current and is the property of of Fairfield Current. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/02/12/organovo-holdings-inc-onvo-stake-raised-by-vanguard-group-inc.html.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Featured Article: Intrinsic Value

Want to see what other hedge funds are holding ONVO?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organovo Holdings Inc (NASDAQ:ONVO).

Institutional Ownership by Quarter for Organovo (NASDAQ:ONVO)

Receive News & Ratings for Organovo Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Organovo and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts